Evogene (EVGN) Director Falk Dan Michael Receives 2,500-Option Grant

What Happened

• Falk Dan Michael, a director of Evogene Ltd. (EVGN), received a grant of 2,500 stock options on September 4, 2026. The options were granted with no cash paid at grant (reported acquisition value $0.00) and are derivative awards under the company's 2021 Share Incentive Plan.
• The exercise price is NIS 1.75 per share, equivalent to $0.58 per share using the Bank of Israel representative rate on the grant date.

Key Details

• Transaction date: September 4, 2026 (Form 4 filed September 30, 2026 — appears to be a late filing; Form 4s are normally due within 2 business days).
• Grant: 2,500 options; exercise price NIS 1.75 = $0.58 per share (footnote F1).
• Vesting: 25% per quarter beginning on the grant date (Sept 4, 2026), fully vested by Sept 4, 2027 (footnote F3).
• Type: Award/Grant of options (derivative). No immediate exercise or sale reported.
• Holdings after transaction: Not specified in the reported row (footnote F4 indicates the row is informational regarding holdings).
• Exhibit: 24.1 Power of Attorney included.

Context

• This is a grant of options (not a purchase or sale of underlying shares). Because these are grants that vest over time, they do not represent an immediate purchase of shares on the open market. Such awards are common as compensation for directors and employees; they give the holder the right to buy shares in the future at the stated exercise price.